One page, thousands of outlets. See who else covered it.
In the amylin race, drug design appears to be a key differentiator. Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug containing an amylin analog and a GLP-1 agonist to ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
"Long sleep duration is more uncommon at mid-life than short sleep duration," the study lead told Newsweek:
Plus news about BioArctic, Enveda, Georgiamune, Kynexis, Tolerance Bio and Network Bio. Amgen puts the "can" in TScan: Amgen is terminating its partnership with TScan Therapeutics, the Waltham…
Republicans are heavily scrutinizing the handling of the pandemic.
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the…
Queen Camilla candidly discusses the emotional challenges of keeping King Charles III's cancer diagnosis private, revealing how it affected her during a recent charity visit.
The Political Declaration to be adopted at the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR) on 25 September has been modified since being placed under the…
